# A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

> **NCT01730768** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 147 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** AQW051
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01730768
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01730768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01730768, "A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01730768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*